Aethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 299,300 shares, a decline of 45.1% from the September 30th total of 544,800 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is presently 0.2 days.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Aethlon Medical in a research report on Wednesday, October 23rd. They set a “sell” rating on the stock.
Check Out Our Latest Stock Report on AEMD
Aethlon Medical Stock Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10. During the same period last year, the business earned ($1.30) EPS. Research analysts forecast that Aethlon Medical will post -1.1 earnings per share for the current year.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Featured Articles
- Five stocks we like better than Aethlon Medical
- How to Start Investing in Real Estate
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Conference Calls and Individual Investors
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Election Stocks: How Elections Affect the Stock Market
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.